Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time Limited Acalabrutinib and Obinutuzumab in Front-Line CLL/SLL
NCT04722172Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2021
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 36 months. Started May 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04722172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722172.